Hangzhou Biotest Biotech Co.Ltd(688767) previously released the performance express, which showed that the company achieved a total operating revenue of 1.818 billion yuan in 2021, an increase of 110.09% over the previous year; The net profit attributable to the owners of the parent company was 833 million yuan, an increase of 91.32% over the previous year Hangzhou Biotest Biotech Co.Ltd(688767) said that the company actively responded to the global demand for covid-19 testing products, continuously developed high-quality covid-19 testing products, opened up new markets and new customers, and the covid-19 antigen family self-test kit produced by the company obtained overseas certification such as EU CE certification, which promoted the surge in the number of foreign trade orders, resulting in a significant increase in the company’s operating performance compared with the same period last year.
Regarding the production capacity of related products, Hangzhou Biotest Biotech Co.Ltd(688767) said that affected by the Omicron mutation virus, the market demand for related products has also increased significantly since November 2021. The company responded positively, and urgently launched the new park of future science and Technology City in November 2021 to accelerate the production capacity in various ways to meet the needs of customers. On the basis of ensuring the normalized demand, the company also made reasonable deployment and expanded production in a rhythmic and planned manner, At present, it can basically meet the requirements.
Public information shows that Hangzhou Biotest Biotech Co.Ltd(688767) since its establishment, it has been focusing on the field of POCT (real-time test), mainly engaged in the R & D, production and sales of POCT diagnostic reagents. It is one of the leading enterprises in China’s POCT industry and one of the manufacturers with a relatively complete variety of POCT diagnostic reagents in the world.
